viernes, 22 de enero de 2016

Necitumumab - National Cancer Institute ll NUEVO CAPÍTULO MÉDICO 2016

Necitumumab - National Cancer Institute

National Cancer Institute

New Drug for Squamous Non-Small Cell Lung Cancer

A new summary about the drug necitumumab. It was recently approved by the FDA to treat squamous non-small cell lung cancer that has metastasized.

National Cancer Institute

Necitumumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
(NEH-sih-TOO-moo-mab)
This page contains brief information about necitumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Portrazza
FDA Approved
Yes

Use in Cancer

Necitumumab is approved to be used with gemcitabine and cisplatin to treat:
Necitumumab is also being studied in the treatment of other types of cancer.

More About Necitumumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Research Results

Lung Cancer Precision Medicine Trials: Adapting to Progress - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Necitumumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

No hay comentarios:

Publicar un comentario